by kelsey@oswaldmarketing.com | Jun 30, 2025 | Success Stories
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000... 
by kelsey@oswaldmarketing.com | May 14, 2025 | Success Stories
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine Atzumi™ (dihydroergotamine (DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or...